Neuren Pharmaceuticals revenue and financials
In the fiscal year ended December 2025, Neuren Pharmaceuticals reported revenue of $64.65M (−70.18% year over year). Net income was $30.44M, a net margin of 47.1%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- −70.18%
- 2025 vs 2024
- Net income growth
- −78.57%
- 2025 vs 2024
- Net margin
- 47.1%
- 2024: 65.5%
How Neuren Pharmaceuticals is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 146.0% a year on average over the last 5 years
Compound annual growth rate: from $717K in 2020 to $64.65M in 2025.
Operating margin rose from −4.7% to 34.1%
Operating income over revenue, 2022 → 2025: 38.8 percentage points.
Profits turn into cash: free cash flow equal to 91% of net income
Totals for fiscal years 2023–2025: free cash flow $298.99M, net income $329.56M.
Shares outstanding up 22.1% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 4 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of AUD; per-share values in AUD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 64.6 | 217 | 232 | 15.4 | 3.2 | 0.7 | 0.5 | 14.0 | 0.6 | 3.2 |
| Cost of revenue | 36.4 | 33.0 | 26.8 | 12.7 | 9.5 | 7.8 | 9.9 | 6.1 | 5.1 | 13.3 |
| Gross profit | 28.3 | 184 | 205 | 2.7 | -6.3 | -7.0 | -9.4 | 7.9 | -4.5 | -10.2 |
| Selling, general and administrative | 6.2 | 4.7 | 5.9 | 3.4 | 1.9 | 1.8 | 1.7 | 2.1 | 1.6 | 1.8 |
| Research and development | 36.4 | 33.0 | 26.8 | 12.7 | — | — | — | — | — | — |
| Operating income | 22.0 | 179 | 199 | -0.7 | -8.2 | -8.8 | -11.1 | 5.8 | -6.1 | -12.0 |
| EBIT | 22.0 | 179 | 199 | -0.7 | -8.2 | -8.8 | -11.1 | 5.8 | -6.1 | -12.0 |
| EBITDA | 22.1 | 179 | 199 | -0.7 | -8.2 | -8.8 | -11.1 | 5.9 | -6.0 | -11.9 |
| Pre-tax income | 38.9 | 183 | 205 | 0.2 | -7.8 | -9.2 | -10.8 | 3.1 | 3.3 | -12.0 |
| Income tax | 8.5 | 40.9 | 48.1 | 0.0 | — | — | — | — | — | — |
| Net income | 30.4 | 142 | 157 | 0.2 | -7.8 | -9.2 | -10.8 | 3.1 | 3.3 | -12.0 |
| Net income to common shareholders | 30.4 | 142 | 157 | 0.2 | -7.8 | -9.2 | -10.8 | 3.1 | 3.3 | -12.0 |
| Basic EPS | 0.24 | 1.11 | 1.24 | 0.00 | -0.07 | -0.09 | -0.11 | 0.03 | 0.04 | -0.14 |
| Diluted EPS | 0.23 | 1.09 | 1.20 | 0.00 | -0.07 | -0.09 | -0.11 | 0.03 | 0.03 | -0.14 |
| Average shares (basic) | 128 | 128 | 127 | 126 | 118 | 107 | 100 | 99.0 | 92.0 | 84.7 |
| Average shares (diluted) | 131 | 131 | 131 | 129 | 119 | 107 | 100 | 99.8 | 93.0 | 84.7 |
Amounts in millions of AUD; per-share values in AUD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 33.2 | 36.4 | 28.3 | 191 | 26.2 | 169 | 62.9 | 15.4 | — | 3.2 |
| Cost of revenue | 27.4 | 21.5 | 14.9 | 15.1 | 17.9 | 15.0 | 11.7 | 8.1 | 4.6 | 2.6 |
| Gross profit | 5.7 | 14.9 | 13.4 | 176 | 8.4 | 154 | 51.2 | 7.3 | -4.6 | 0.6 |
| Selling, general and administrative | 3.0 | 3.7 | 2.5 | 2.3 | 2.4 | 2.9 | 3.0 | 1.9 | 1.6 | 1.1 |
| Operating income | 2.7 | 11.1 | 10.9 | 173 | 6.0 | 151 | 48.1 | 6.6 | -7.3 | -0.0 |
| EBIT | 2.7 | 11.1 | 10.9 | 173 | 6.0 | 151 | 48.1 | 6.6 | -7.3 | -0.0 |
| EBITDA | 2.7 | 11.2 | 10.9 | 173 | 6.0 | 151 | 48.1 | 6.6 | -7.3 | -0.0 |
| Pre-tax income | 7.6 | 19.2 | 19.7 | 171 | 11.8 | 156 | 49.6 | 7.2 | -7.1 | 0.2 |
| Income tax | 2.8 | 3.8 | 4.7 | 37.1 | 3.8 | 46.2 | 1.8 | — | — | — |
| Net income | 4.9 | 15.4 | 15.0 | 134 | 8.0 | 109 | 47.8 | 7.2 | -7.1 | 0.2 |
| Net income to common shareholders | 4.9 | 15.4 | 15.0 | 134 | 8.0 | 109 | 47.8 | 7.2 | -7.1 | 0.2 |
| Basic EPS | 0.04 | 0.12 | 0.12 | 1.05 | 0.06 | 0.86 | 0.38 | 0.06 | -0.06 | 0.00 |
| Diluted EPS | 0.04 | 0.12 | 0.12 | 1.03 | 0.06 | 0.83 | 0.37 | 0.05 | -0.06 | 0.00 |
| Average shares (basic) | 127 | 130 | 127 | 128 | 128 | 128 | 126 | 126 | 126 | 121 |
| Average shares (diluted) | 127 | 133 | 129 | 131 | 131 | 131 | 130 | 132 | 126 | 123 |
| Dividend per share | 0.15 | — | — | — | — | — | — | — | — | — |
Amounts in millions of AUD; per-share values in AUD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 343 | 410 | 248 | 43.3 | 40.1 | 25.0 | 14.4 | 26.6 | 17.9 | 6.2 |
| Current assets | 332 | 399 | 247 | 43.2 | 40.0 | 24.9 | 14.4 | 26.6 | 16.1 | 6.1 |
| Cash and equivalents | 4.2 | 3.2 | 17.1 | 40.2 | 36.8 | 24.2 | 13.8 | 23.6 | 4.7 | 5.1 |
| Short-term investments | 292 | 219 | 211 | — | — | — | — | — | — | — |
| Receivables | 26.5 | 175 | 14.4 | 1.1 | 1.4 | 0.8 | 0.6 | 0.9 | 0.7 | 1.0 |
| Net property, plant and equipment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other intangible assets | — | — | — | — | — | — | — | 0.0 | 0.1 | 0.1 |
| Current liabilities | 4.3 | 45.8 | 42.8 | 1.7 | 0.8 | 0.8 | 0.6 | 2.0 | 1.6 | 2.0 |
| Accounts payable | 0.9 | 1.4 | 0.7 | 0.3 | 0.2 | 0.2 | 0.3 | 1.3 | 0.7 | 1.0 |
| Total liabilities | 4.4 | 45.8 | 42.8 | 1.7 | 0.8 | 0.8 | 0.6 | 2.0 | 1.6 | 2.0 |
| Total equity (incl. minority) | 338 | 364 | 205 | 41.6 | 39.3 | 24.2 | 13.8 | 24.7 | 16.4 | 4.2 |
| Retained earnings | 211 | 180 | 38.4 | -119 | -119 | -111 | -104 | -93.3 | -97.4 | -98.4 |
Amounts in millions of AUD; per-share values in AUD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 341 | 343 | 331 | 410 | 228 | 248 | 97.5 | 43.3 | 34.6 | 40.1 |
| Current assets | 333 | 332 | 320 | 399 | 228 | 247 | 96.4 | 43.2 | 34.6 | 40.0 |
| Cash and equivalents | 26.9 | 4.2 | 5.9 | 3.2 | 2.6 | 17.1 | 38.4 | 40.2 | 31.1 | 36.8 |
| Short-term investments | 260 | 292 | 294 | 219 | 211 | 211 | 47.3 | — | — | — |
| Receivables | 33.3 | 26.5 | 20.7 | 175 | 14.9 | 14.4 | 10.6 | 1.1 | 3.5 | 1.4 |
| Net property, plant and equipment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current liabilities | 7.2 | 4.3 | 7.9 | 45.8 | 9.0 | 42.8 | 6.0 | 1.7 | 1.1 | 0.8 |
| Accounts payable | 7.2 | 0.9 | 6.7 | 1.4 | 4.5 | 0.7 | 3.1 | 0.3 | 1.1 | 0.2 |
| Total liabilities | 7.2 | 4.4 | 8.0 | 45.8 | 9.0 | 42.8 | 6.0 | 1.7 | 1.1 | 0.8 |
| Total equity (incl. minority) | 333 | 338 | 323 | 364 | 219 | 205 | 91.5 | 41.6 | 33.5 | 39.3 |
| Retained earnings | 216 | 211 | 195 | 180 | 46.4 | 38.4 | -70.9 | -119 | -126 | -119 |
Amounts in millions of AUD; per-share values in AUD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 125 | -11.3 | 185 | 3.6 | -10.0 | -8.1 | -11.7 | 6.4 | -5.6 | -12.4 |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| Capital expenditure | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | — | — | -0.0 |
| Investing cash flow | -88.0 | 4.1 | -211 | -0.0 | -0.0 | -0.0 | -0.0 | — | — | -0.0 |
| Financing cash flow | -33.2 | -8.8 | 3.6 | -0.0 | 22.2 | 19.1 | 1.9 | 11.7 | 5.3 | 0.9 |
| Share repurchases | -39.6 | -10.4 | -0.0 | -0.0 | — | — | — | — | — | — |
| Effect of exchange rates | -3.1 | 2.0 | -0.1 | -0.2 | 0.4 | -0.7 | 0.1 | 0.7 | -0.1 | -0.1 |
| Net change in cash | 1.1 | -13.9 | -23.1 | 3.4 | 12.6 | 10.3 | -9.7 | 18.9 | -0.3 | -11.6 |
| Free cash flow | 125 | -11.3 | 185 | 3.6 | -10.0 | — | — | — | — | — |
| Levered free cash flow | 117 | -42.3 | 153 | 2.6 | -6.8 | -5.1 | -5.8 | 12.4 | -14.0 | -8.0 |
Amounts in millions of AUD; per-share values in AUD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 8.0 | -2.9 | 128 | 9.3 | -20.5 | 140 | 44.9 | 9.4 | -5.8 | -3.8 |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Capital expenditure | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 |
| Investing cash flow | 18.8 | -2.4 | -85.6 | 3.3 | 0.8 | -164 | -47.3 | -0.0 | -0.0 | -0.0 |
| Financing cash flow | -2.2 | 5.0 | -38.2 | -10.4 | 1.7 | 2.5 | 1.1 | 0.0 | -0.0 | 22.2 |
| Share repurchases | -3.9 | 0.0 | -39.6 | -10.4 | — | — | — | — | — | — |
| Effect of exchange rates | -1.9 | -1.3 | -1.8 | -1.6 | 3.5 | 0.3 | -0.5 | -0.3 | 0.1 | 0.2 |
| Net change in cash | 22.7 | -1.7 | 2.8 | 0.6 | -14.5 | -21.3 | -1.8 | 9.1 | -5.7 | 18.6 |
| Free cash flow | 8.0 | -2.9 | 128 | 9.3 | -20.5 | 140 | 44.9 | 9.4 | -5.8 | -3.8 |
| Levered free cash flow | -4.7 | -8.9 | 126 | -16.7 | -25.5 | 125 | 27.8 | 6.0 | -3.4 | -3.6 |
Financial statements of similar companies
Companies in the group: same industry, similar size
